Correlation Between Nanoform Finland and Herantis Pharma

Can any of the company-specific risk be diversified away by investing in both Nanoform Finland and Herantis Pharma at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Nanoform Finland and Herantis Pharma into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Nanoform Finland Plc and Herantis Pharma Oyj, you can compare the effects of market volatilities on Nanoform Finland and Herantis Pharma and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Nanoform Finland with a short position of Herantis Pharma. Check out your portfolio center. Please also check ongoing floating volatility patterns of Nanoform Finland and Herantis Pharma.

Diversification Opportunities for Nanoform Finland and Herantis Pharma

0.04

Correlation Coefficient

Nanoform Finland  Herantis Pharma

Significant diversification

The 3 months correlation between Nanoform and Herantis is 0.04. Overlapping area represents the amount of risk that can be diversified away by holding Nanoform Finland Plc and Herantis Pharma Oyj in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Herantis Pharma Oyj and Nanoform Finland is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Nanoform Finland Plc are associated (or correlated) with Herantis Pharma. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Herantis Pharma Oyj has no effect on the direction of Nanoform Finland i.e., Nanoform Finland and Herantis Pharma go up and down completely randomly.

Pair Corralation between Nanoform Finland and Herantis Pharma

Assuming the 90 days trading horizon Nanoform Finland Plc is expected to under-perform the Herantis Pharma. In addition to that, Nanoform Finland is 1.07 times more volatile than Herantis Pharma Oyj. It trades about -0.02 of its total potential returns per unit of risk. Herantis Pharma Oyj is currently generating about 0.0 per unit of volatility. If you would invest  221.00  in Herantis Pharma Oyj on October 11, 2024 and sell it today you would lose (58.00) from holding Herantis Pharma Oyj or give up 26.24% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Insignificant
Accuracy	100.0%
Values	Daily Returns

Nanoform Finland Plc  vs.  Herantis Pharma Oyj

Nanoform Finland Plc

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Nanoform Finland Plc has generated negative risk-adjusted returns adding no value to investors with long positions. Despite inconsistent performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in February 2025. The current disturbance may also be a sign of long term up-swing for the company investors.

Herantis Pharma Oyj

Risk-Adjusted Performance

4 of 100

Insignificant

Compared to the overall equity markets, risk-adjusted returns on investments in Herantis Pharma Oyj are ranked lower than 4 (%) of all global equities and portfolios over the last 90 days. Despite fairly weak technical indicators, Herantis Pharma may actually be approaching a critical reversion point that can send shares even higher in February 2025.

Pair Trading with Nanoform Finland and Herantis Pharma

The main advantage of trading using opposite Nanoform Finland and Herantis Pharma positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Nanoform Finland position performs unexpectedly, Herantis Pharma can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Herantis Pharma will offset losses from the drop in Herantis Pharma's long position.

The idea behind Nanoform Finland Plc and Herantis Pharma Oyj pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.